Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.77 +1.1%	$1.84	$1.00 ▼ $5.22	$42.39M	0.77	335,725 shs	3,375 shs
CELZ Creative Medical Technology	$2.14 -1.8%	$2.07	$1.69 ▼ $6.90	$5.53M	1.98	53,687 shs	16,530 shs
NRXP NRx Pharmaceuticals	$3.50 +1.7%	$2.38	$1.10 ▼ $6.01	$60.86M	1.54	412,563 shs	125,064 shs
SRZN Surrozen	$9.47 -0.2%	$8.93	$5.90 ▼ $18.17	$81.09M	0.57	21,063 shs	1,697 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-15.87%	-14.22%	+17.45%	-45.40%
CELZ Creative Medical Technology	0.00%	-9.37%	+7.23%	-32.52%	-47.93%
NRXP NRx Pharmaceuticals	0.00%	+5.20%	+40.41%	+67.80%	+13.53%
SRZN Surrozen	0.00%	+11.53%	+33.52%	-18.28%	-15.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELU Celularity	0.5195 of 5 stars	0.0	2.0	1.9	1.7	0.6
CELZ Creative Medical Technology	0.4336 of 5 stars	0.0	3.0	0.9	0.0	1.3
NRXP NRx Pharmaceuticals	2.3322 of 5 stars	3.6	1.0	4.0	0.8	0.6
SRZN Surrozen	3.8171 of 5 stars	3.5	3.0	3.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	0.00	N/A	N/A	N/A
CELZ Creative Medical Technology	0.00	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	714.29% Upside
SRZN Surrozen	3.00	Buy	$38.50	306.76% Upside

Current Analyst Ratings Breakdown

Latest CELZ, CELU, NRXP, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
4/2/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/20/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/17/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$54.22M	0.78	$7.38 per share	0.24	$2.11 per share	0.84
CELZ Creative Medical Technology	$14K	395.29	N/A	N/A	$7.48 per share	0.29
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.38) per share	N/A
SRZN Surrozen	$11.64M	6.96	N/A	N/A	$18.39 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$196.29M	-$2.65	N/A	∞	N/A	-72.72%	-119.53%	-25.40%	7/28/2025 (Estimated)
CELZ Creative Medical Technology	-$5.29M	-$3.81	N/A	N/A	N/A	N/A	-63.05%	-60.42%	8/8/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$30.15M	-$2.01	N/A	N/A	N/A	N/A	N/A	-449.16%	8/13/2025 (Estimated)
SRZN Surrozen	-$43.04M	-$24.96	N/A	N/A	N/A	N/A	-120.51%	-54.68%	8/11/2025 (Estimated)

Latest CELZ, CELU, NRXP, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/9/2025	Q1 2025	CELZ Creative Medical Technology	-$0.52	-$0.83	-$0.31	-$0.83	N/A	$0.00 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/8/2025	Q4 2024	CELU Celularity	-$1.50	-$0.59	+$0.91	-$0.59	$5.20 million	$18.13 million
3/31/2025	Q4 2024	SRZN Surrozen	-$2.54	-$9.10	-$6.56	-$9.10	N/A	$0.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.19	0.14
CELZ Creative Medical Technology	N/A	19.13	19.12
NRXP NRx Pharmaceuticals	N/A	0.20	0.20
SRZN Surrozen	N/A	7.40	7.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
CELZ Creative Medical Technology	1.42%
NRXP NRx Pharmaceuticals	4.27%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
CELU Celularity	22.10%
CELZ Creative Medical Technology	2.80%
NRXP NRx Pharmaceuticals	19.00%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	23.95 million	18.55 million	Optionable
CELZ Creative Medical Technology	5	2.59 million	1.70 million	Not Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	12.72 million	Optionable
SRZN Surrozen	80	8.56 million	1.84 million	Not Optionable

CELZ, CELU, NRXP, and SRZN Headlines

Recent News About These Companies

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 16.0% in May

June 3, 2025 | marketbeat.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 2, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

March 29, 2025 | insidertrades.com

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

March 27, 2025 | markets.businessinsider.com

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

March 26, 2025 | markets.businessinsider.com

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development

March 24, 2025 | quiverquant.com

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

March 24, 2025 | globenewswire.com

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation

January 30, 2025 | msn.com

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating

January 30, 2025 | msn.com

(SRZN) Trading Advice

January 30, 2025 | news.stocktradersdaily.com

Surrozen initiated with a Buy at H.C. Wainwright

January 30, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ, CELU, NRXP, and SRZN Company Descriptions

Celularity NASDAQ:CELU

$1.77 +0.02 (+1.14%)

As of 12:15 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Creative Medical Technology NASDAQ:CELZ

$2.14 -0.04 (-1.83%)

As of 12:11 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

NRx Pharmaceuticals NASDAQ:NRXP

$3.50 +0.06 (+1.74%)

As of 12:15 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Surrozen NASDAQ:SRZN

$9.46 -0.02 (-0.16%)

As of 12:15 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time